Objective: To explore the views of members of the British Menopause Society on the management of women with unscheduled bleeding on hormone replacement therapy.
Study Design: An electronic cross-sectional questionnaire survey.
Main Outcome Measures: Investigations, treatment options and preferences for the management of women with unscheduled bleeding on hormone replacement therapy.
Results: A total of 91/178 (51%) clinicians investigate patients with unscheduled bleeding within three to six months of starting sequential hormone replacement therapy (seq-HRT) versus 83/178 (47%) for continuous combined hormone replacement therapy (con-HRT). A total of 52/178 (29%) versus 54/178 (30%) would investigate unscheduled bleeding continuing beyond six months while 18/178 (10%) versus 26/178 (15%) would investigate within three months. Assessment is requested as urgent by 88/176 (50%) clinicians, routine by 47/176 (27%) and a two-week-wait-suspected cancer referral by 41/176 (23%). A total of 97/178 (55%) clinicians would continue seq-HRT and refer versus 117/178 (66%) for con-HRT. A total of 46/178 (26%) clinicians would change the progestogen preparation in women with unscheduled bleeding on seq-HRT. For women on con-HRT, 12/178 (7%) clinicians would change to seq-HRT and 8/178 (5%) to the Mirena IUS. The Mirena IUS is the preferred progestogen for 81/178 (45%) of clinicians when prescribing hormone replacement therapy.
Conclusions: There is a varied approach in the practise amongst British Menopause Society members to managing women with unscheduled bleeding on hormone replacement therapy. Further research is needed to determine the optimal assessment pathways for women with unscheduled bleeding on hormone replacement therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/20533691211024415 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tips and tricks for the management of contraceptive etonogestrel implant in clinical practice: an Expert Opinion.
Eur J Contracept Reprod Health Care
December 2024
Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Article Synopsis
- The global use of long-acting reversible contraceptives (LARCs) is rising because they more effectively prevent unintended pregnancies compared to short-acting methods, especially in teens.
- LARCs include options like intrauterine devices and subcutaneous implants, with specialized training required for their application.
- This Expert Opinion focuses on the etonogestrel (ENG)-releasing implant, offering updated guidance on insertion, removal, and managing unscheduled bleeding based on extensive clinical experience.
Postpartum Hemorrhagic Morbidity with Scheduled versus Unscheduled Cesarean Delivery at Term.
Am J Perinatol
November 2024
Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas.
Objective: This study aimed to compare the composite maternal hemorrhagic outcomes (CMHOs) among term (≥37 weeks) singletons who had scheduled versus unscheduled cesarean deliveries (CDs). A subgroup analysis was done for those without prior uterine surgeries.
Study Design: Retrospectively, we identified all singletons at term who had CDs.
Predictive Factors of Unexpected Hospitalization within Six Months of Undergoing Percutaneous Coronary Intervention in Patients with Chronic Coronary Disease.
Intern Med
November 2024
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan.
Background Recent guidelines recommend dual antiplatelet therapy (DAPT) for six months following percutaneous coronary intervention (PCI) in patients with chronic coronary disease, as unexpected hospitalization can trigger DAPT discontinuation. This study evaluated the predictive factors for unexpected hospitalization within six months after PCI in patients with chronic coronary disease. Methods This prospective multicenter study included 412 patients who underwent PCI for chronic coronary disease.
View Article and Find Full Text PDFA randomised double-blind trial to determine the bleeding profile of the prolonged-release contraceptive dienogest 2 mg/ethinylestradiol 0.02 mg versus an immediate-release formulation of drospirenone 3 mg/ethinylestradiol 0.02 mg.
Eur J Contracept Reprod Health Care
September 2024
Exeltis Healthcare, Ismaning, Germany.
Background: Dienogest (DNG) 2 mg/ethinylestradiol (EE) 0.02 mg is the first low-dose combined oral contraceptive (COC) with a prolonged-release formulation that allows stable plasma concentrations and has high contraceptive efficacy (Pearl index: 0.2).
View Article and Find Full Text PDFTreatments of unscheduled vaginal bleeding due to progestin-only contraception.
Cochrane Database Syst Rev
September 2024
Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA.
Article Synopsis
- The protocol outlines a Cochrane Review aimed at assessing treatment options for unscheduled vaginal bleeding in premenopausal women.
- The review will focus on evaluating the effectiveness, safety, and side effects of progestin-only pills as a treatment method.
- The overall goal is to provide reliable evidence on the use of these treatments for women experiencing this health issue.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!